
Saturday, June 28, 2025 1:46:59 PM
Per your comments,
"Really?? BP's have completely ignored NWBO. They've had years to buy it for pocket change. No BP does deals with OTCs -- none have in the last decade. Merck. who's part of the SPORE trial, sees all the data and has made at least three other oncology deals and passed on NWBO. Nobody is going to do a deal with NWBO because they know the FDA has told NWBO they won't accept the DCVax-L P3 trial."
1) The BPs have ignored NWBO since NWBOs products would jeopardize the BPs profits from their current SOC. IMPO.
2) Yes, the BPs had years to buy NWBO, but they know the true value of NWBO and could not afford NWBO's stock price, IMPO.
3) Per your comments "No BP does deals with OTCs -- none have in the last decade", this topic has been addressed multiple times, the BPs know NWBO's capabilities and NWBOs disruptive factors to their bottom line, IMPO.
4) Per your comments, "Merck. who's part of the SPORE trial, sees all the data and has made at least three other oncology deals and passed on NWBO." Merck knows the value of NWBO and how DCVax could add value to Merck's products, you know this but fail to address the true facts, IMPO.
5) Per your comments, "Nobody is going to do a deal with NWBO because they know the FDA has told NWBO they won't accept the DCVax-L P3 trial." Wow, you know that the FDA is fully aware of the fact that DCVax works and it's only a matter of time before FDA should approve DCVax, IMPO.
In all, you know that DCVax works, and it should have been approved already, IMPO

Recent NWBO News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
- Investors Watching Two Small-Caps for News on Potential Major Advancements in Cancer Treatments • AllPennyStocks.com • 01/13/2025 01:56:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/26/2024 10:07:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2024 09:29:14 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 09:10:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2024 09:24:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
Branded Legacy Inc. Announces Leadership Transition and Pending Merger with Innovative Addiction Therapeutics Company Projecting $40 Million in First-Year Revenue • BLEG • Jul 14, 2025 1:23 PM
VAYK Project 100% Revenue Growth Before Half Year Report • VAYK • Jul 14, 2025 8:58 AM
Glidelogic Corp. Announces Release of First AI-Generated Novel "The Thirteenth Proposal" • GDLG • Jul 11, 2025 12:20 PM
Fifty1 AI Labs' REVIVE Clinical Trial Redefines Long COVID Treatment, Pioneering AI-Driven Therapies and Propelling Fifty 1 Labs, Inc. Toward $50M Valuation and Global Biotech Leadership • FITY • Jul 10, 2025 8:30 AM
Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB™, its New Sublingual Pre-Workout Supplement • ASBP • Jul 9, 2025 9:15 AM
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers • IBRX • Jul 9, 2025 9:00 AM